News articles about Immunomedics (NASDAQ:IMMU) have trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Immunomedics earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 44.830804269048 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
A number of research firms have recently weighed in on IMMU. Jefferies Group LLC upped their price target on shares of Immunomedics from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, October 9th. Zacks Investment Research raised shares of Immunomedics from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research note on Wednesday, October 4th. BidaskClub raised shares of Immunomedics from a “hold” rating to a “buy” rating in a research note on Wednesday, August 23rd. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $15.00 price target on shares of Immunomedics in a research note on Monday, July 24th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Immunomedics presently has a consensus rating of “Buy” and an average price target of $15.33.
Immunomedics (IMMU) opened at 11.01 on Friday. The stock’s market capitalization is $1.23 billion. Immunomedics has a one year low of $2.02 and a one year high of $14.48. The stock’s 50 day moving average is $11.94 and its 200 day moving average is $9.01.
Immunomedics (NASDAQ:IMMU) last released its quarterly earnings data on Wednesday, August 16th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.13). The firm had revenue of $0.64 million during the quarter, compared to the consensus estimate of $0.75 million. During the same period last year, the firm posted ($0.17) earnings per share. The firm’s revenue was down 31.2% on a year-over-year basis. On average, equities analysts forecast that Immunomedics will post ($0.53) EPS for the current year.
In other Immunomedics news, insider David M. Goldenberg sold 20,000 shares of Immunomedics stock in a transaction on Friday, September 1st. The stock was sold at an average price of $12.64, for a total value of $252,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Cynthia L. Goldenberg sold 40,000 shares of Immunomedics stock in a transaction on Monday, August 28th. The shares were sold at an average price of $10.72, for a total value of $428,800.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 100,000 shares of company stock valued at $1,051,200. Insiders own 6.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Immunomedics (IMMU) Share Price” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/10/27/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-immunomedics-immu-stock-price.html.
Immunomedics Company Profile
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.